Blinatumomab

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].

Product Specifications

CAS Number

[853426-35-4]

Product Name Alternative

Anatumomab; bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO

UNSPSC

12352203

Target

CD19

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/blinatumomab.html

Purity

98.78

Solubility

H2O

Smiles

[Blinatumomab]

Molecular Weight

(54.09 kDa)

References & Citations

[1]Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376 (9) :836-847. |[2]Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003 Apr 15;170 (8) :4397-402.|[3]Hoffman LM, et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE (®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014 Mar 31;4:63. |[4]Zhang R, et al. The establishment and application of CD3E humanized mice in immunotherapy[J]. Experimental Animals, 2022, 71 (4) : 442-450.